MCID: ORL015
MIFTS: 55

Oral Squamous Cell Carcinoma

Categories: Rare diseases, Cancer diseases, Oral diseases, Gastrointestinal diseases

Aliases & Classifications for Oral Squamous Cell Carcinoma

MalaCards integrated aliases for Oral Squamous Cell Carcinoma:

Name: Oral Squamous Cell Carcinoma 12 50 14
Squamous Cell Carcinoma of Mouth 69
Mouth Squamous Cell Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050866

Summaries for Oral Squamous Cell Carcinoma

Disease Ontology : 12 An oral cavity cancer that has material basis in squamous cells.

MalaCards based summary : Oral Squamous Cell Carcinoma, also known as squamous cell carcinoma of mouth, is related to squamous cell carcinoma and split hand split foot nystagmus. An important gene associated with Oral Squamous Cell Carcinoma is HRAS (HRas Proto-Oncogene, GTPase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Cetuximab and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include lymph node, lung and endothelial, and related phenotypes are Decreased cell migration and Decreased viability

Related Diseases for Oral Squamous Cell Carcinoma

Diseases related to Oral Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 233)
id Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 11.3
2 split hand split foot nystagmus 11.0 CDKN2A HRAS TP53
3 adenocarcinoma in situ 11.0 CDKN2A HRAS TP53
4 olfactory neural tumor 11.0 CDKN2A HRAS TP53
5 cervical adenoid cystic carcinoma 11.0 CDKN2A TP53
6 organic mood syndrome 11.0 EGFR PDPN
7 advanced sleep phase syndrome 11.0 CDKN2A HRAS TP53
8 pediatric infratentorial ependymoma 11.0 EGFR TP53
9 sparse hair ptosis mental retardation 11.0 EGFR TP53 VEGFA
10 stenosis of lacrimal punctum 11.0 CCND1 EGFR HRAS
11 chorioangioma 11.0 CCND1 EGFR HRAS
12 skeletal tuberculosis 11.0 CCND1 CDKN2A
13 multiple carboxylase deficiency 11.0 CDKN2A EGFR TP53
14 bladder squamous cell carcinoma 10.9 CCND1 CDKN2A TP53
15 distal monosomy 7q36 10.9 EGFR TP53 VEGFA
16 middle ear squamous cell carcinoma 10.9 CDKN2A EGFR TP53
17 lacrimal gland mucoepidermoid carcinoma 10.9 CDH1 EGFR TP53
18 epidural neoplasm 10.9 CDKN2A VEGFA VEGFC
19 hip subluxation 10.9 CCND1 EGFR TP53
20 tumor of exocrine pancreas 10.9 CDKN2A EGFR VEGFA
21 secondary hyperparathyroidism of renal origin 10.9 CDKN2A EGFR TP53
22 choriocarcinoma 10.9 CDKN2A TP53 VEGFA
23 acquired hemangioma 10.9 EGFR MMP2 MMP9
24 olfactory neuroblastoma 10.9 EGFR HRAS TP53
25 molluscum contagiosum 10.9 CDKN2A EGFR TP53
26 uterine corpus adenofibroma 10.9 HRAS KRT19 TP53
27 adenosine monophosphate deaminase 1 deficiency 10.9 MMP2 MMP9 VEGFA
28 cecum adenocarcinoma 10.9 CDKN2A EGFR TP53
29 facial arteriovenous malformation 10.9 MMP2 MMP9
30 ritter's disease 10.9 CDKN2A KRT19 TP53
31 lung papillary adenocarcinoma 10.9 CDH1 MMP2 MMP9
32 renal adenoma 10.9 PDPN VEGFA VEGFC
33 oligomeganephronic renal hypoplasia 10.9 MMP2 MMP9 VEGFA
34 fallopian tube leiomyosarcoma 10.9 CDH1 CDKN2A TP53
35 colon squamous cell carcinoma 10.9 CDKN2A MMP2 MMP9
36 myxedema 10.9 CDKN2A EGFR HRAS TP53
37 unilateral retinoblastoma 10.9 CCND1 CDKN1B CDKN2A TP53
38 anaerobic pneumonia 10.9 CDH1 CDKN2A EGFR TP53
39 pharynx cancer 10.9 CCND1 CDKN1B CDKN2A TP53
40 male reproductive organ cancer 10.9 CTNNB1 MMP9 VEGFA
41 post-surgical hypoinsulinemia 10.9 CCND1 CDKN1B CDKN2A TP53
42 benign familial neonatal epilepsy 10.9 PDPN VEGFA VEGFC
43 non-distal trisomy 10q 10.9 EGFR HRAS TP53 VEGFA
44 pancreatic signet ring cell adenocarcinoma 10.9 CDH1 CTNNB1 TP53
45 ossifying fibromyxoid tumor 10.9 HRAS KRT19 TP53
46 glycogen storage disease due to lactate dehydrogenase deficiency 10.9 CTNNB1 TP53
47 childhood type dermatomyositis 10.9 CDH1 CDKN2A EGFR TP53
48 fasciolopsiasis 10.9 CDKN2A MMP2 TP53
49 cleft lip palate dysmorphism kumar type 10.9 CCND1 EGFR TP53 VEGFA
50 fallopian tube mucinous tumor 10.9 CDKN2A EGFR TP53

Graphical network of the top 20 diseases related to Oral Squamous Cell Carcinoma:



Diseases related to Oral Squamous Cell Carcinoma

Symptoms & Phenotypes for Oral Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.55 VEGFC AKT1 CTNNB1 EGFR HRAS
2 Decreased viability GR00055-A-2 9.55 EGFR HRAS
3 Decreased viability GR00221-A-1 9.55 AKT1 CDH1 CDKN1B CDKN2A EGFR HRAS
4 Decreased viability GR00221-A-2 9.55 AKT1 HRAS
5 Decreased viability GR00221-A-3 9.55 AKT1 CDKN2A HRAS
6 Decreased viability GR00221-A-4 9.55 AKT1 CDKN2A EGFR
7 Decreased viability GR00301-A 9.55 CDH1
8 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.35 CTNNB1 EGFR HRAS VEGFA VEGFC

MGI Mouse Phenotypes related to Oral Squamous Cell Carcinoma:

44 (show all 24)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.54 AKT1 CASP3 CCND1 CDH1 CDKN1B CDKN2A
2 homeostasis/metabolism MP:0005376 10.45 MMP2 MMP9 PDPN TP53 VEGFA VEGFC
3 growth/size/body region MP:0005378 10.44 MMP2 MMP9 PDPN TP53 VEGFA AKT1
4 mortality/aging MP:0010768 10.44 HRAS KRT19 MMP2 MMP9 PDPN TP53
5 cellular MP:0005384 10.42 AKT1 CASP3 CCND1 CDH1 CDKN1B CDKN2A
6 immune system MP:0005387 10.38 TP53 VEGFA VEGFC AKT1 CASP3 CCND1
7 digestive/alimentary MP:0005381 10.37 CTNNB1 EGFR KRT19 MMP9 PDPN TP53
8 integument MP:0010771 10.37 CDKN2A CTNNB1 EGFR HRAS KRT19 MMP9
9 behavior/neurological MP:0005386 10.36 AKT1 CASP3 CCND1 CDKN1B CDKN2A CTNNB1
10 endocrine/exocrine gland MP:0005379 10.35 AKT1 CASP3 CCND1 CDH1 CDKN1B CDKN2A
11 hematopoietic system MP:0005397 10.34 AKT1 CASP3 CCND1 CDKN1B CDKN2A CTNNB1
12 neoplasm MP:0002006 10.29 CDKN2A CTNNB1 EGFR HRAS KRT19 MMP2
13 muscle MP:0005369 10.27 AKT1 CASP3 CDKN1B CDKN2A CTNNB1 EGFR
14 nervous system MP:0003631 10.27 HRAS KRT19 MMP2 MMP9 TP53 AKT1
15 craniofacial MP:0005382 10.25 CASP3 CCND1 CDKN1B CTNNB1 EGFR HRAS
16 embryo MP:0005380 10.24 AKT1 CDH1 CDKN2A CTNNB1 EGFR HOPX
17 no phenotypic analysis MP:0003012 10.17 CASP3 CDH1 CDKN1B CDKN2A CTNNB1 EGFR
18 normal MP:0002873 10.1 EGFR HRAS KRT19 MMP2 TP53 VEGFA
19 reproductive system MP:0005389 10.03 AKT1 CASP3 CCND1 CDH1 CDKN1B CDKN2A
20 respiratory system MP:0005388 10 AKT1 CASP3 CCND1 CDKN1B CDKN2A CTNNB1
21 renal/urinary system MP:0005367 9.92 MMP9 TP53 VEGFA CASP3 CDKN1B CTNNB1
22 pigmentation MP:0001186 9.85 CASP3 CDKN1B CDKN2A CTNNB1 EGFR TP53
23 skeleton MP:0005390 9.8 AKT1 CASP3 CCND1 CDKN1B CDKN2A CTNNB1
24 vision/eye MP:0005391 9.32 CASP3 CCND1 CDKN1B CDKN2A CTNNB1 EGFR

Drugs & Therapeutics for Oral Squamous Cell Carcinoma

Drugs for Oral Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 379)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cetuximab Approved Phase 4,Phase 2,Phase 3,Phase 1 205923-56-4 56842117 2333
2
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
3
Cevimeline Approved Phase 4,Phase 3 107233-08-9 83898 25137844
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
5
Morphine Approved, Investigational Phase 4 57-27-2 5288826
6 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
8 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
9 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
10 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
11 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Mitomycins Phase 4,Phase 2
13 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
14 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
15 Cholinergic Agents Phase 4,Phase 3
16 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
18 Analgesics Phase 4,Phase 3,Phase 1,Phase 2
19 Adjuvants, Anesthesia Phase 4
20 Anesthetics Phase 4,Phase 2
21 Anesthetics, General Phase 4
22 Anesthetics, Intravenous Phase 4
23 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Early Phase 1
24 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
25 Analgesics, Opioid Phase 4
26 Narcotics Phase 4
27 arginine Nutraceutical Phase 4,Phase 2,Phase 1
28 Omega 3 Fatty Acid Nutraceutical Phase 4,Phase 2
29
Cisplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
30
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
31
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
32
Aldesleukin Approved Phase 3,Phase 1 85898-30-2, 110942-02-4
33
Citalopram Approved Phase 3 59729-33-8 2771
34
Tegafur Approved Phase 3,Phase 2 17902-23-7 5386
35
Epinephrine Approved, Vet_approved Phase 3,Phase 2 51-43-4 5816
36
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
37 Racepinephrine Approved Phase 3,Phase 2
38
Carboplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 498142 38904
39
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
40
Oxaliplatin Approved, Investigational Phase 3,Phase 2 61825-94-3 5310940 9887054 43805 6857599
41
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
42
Pilocarpine Approved Phase 3 54-71-7, 92-13-7 5910
43
Dapsone Approved, Investigational Phase 3 80-08-0 2955
44
Doxycycline Approved, Investigational, Vet_approved Phase 3,Phase 2 564-25-0 54671203
45
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
46
Doxepin Approved Phase 3 1668-19-5 667477 667468
47
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
48
Isotretinoin Approved Phase 3,Phase 2 4759-48-2 5538 5282379
49
Fluconazole Approved Phase 2, Phase 3 86386-73-4 3365
50
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1,Early Phase 1 22916-47-8 4189

Interventional clinical trials:

(show top 50) (show all 536)

id Name Status NCT ID Phase Drugs
1 Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Unknown status NCT02015650 Phase 4 Cetuximab;Mitomycin-C/ 5-Fluorouracil
2 Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia Completed NCT00466388 Phase 4 Cevimeline
3 A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients Completed NCT01283906 Phase 4
4 Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Head & Neck Cancer Patients Completed NCT02622880 Phase 4
5 Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip Completed NCT00868088 Phase 4
6 Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy Recruiting NCT02869321 Phase 4 Fentanyl;Morphine Sulfate;Fentanyl placebo;Morphine Sulfate placebo
7 Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL Unknown status NCT01039298 Phase 3
8 Oral Cancer Adjuvant Therapy (OCAT) Trial Unknown status NCT00193843 Phase 3
9 Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma Unknown status NCT01947062 Phase 3 Intravenous Cisplatin & etoposide;Intravenous Cisplatin & etoposide along with oral cyclophosphamide
10 Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth Cancer Unknown status NCT00002747 Phase 3 cisplatin;fluorouracil
11 Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx Unknown status NCT00002702 Phase 3
12 Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment Unknown status NCT00935675 Phase 3 Escitalopram
13 S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil
14 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
15 TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma Completed NCT01542931 Phase 2, Phase 3 TPF induction chemotherapy
16 Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients Completed NCT00201383 Phase 3 cisplatin
17 Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma Completed NCT00201279 Phase 3 13-cis Retino Acid
18 Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients Completed NCT01439724 Phase 3
19 Phase II Trial of Allovectin-7® for Head and Neck Cancer Completed NCT00050388 Phase 3
20 LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy Completed NCT01345682 Phase 3 Afatinib;Methotrexate
21 Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Completed NCT00158652 Phase 3 5FU, Paraplatin
22 Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Completed NCT01434394 Phase 2, Phase 3 Neo-adjuvant Erbitux-based chemotherapy
23 Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00003139 Phase 3 pilocarpine hydrochloride
24 Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
25 Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Completed NCT00101582 Phase 3 Placebo;palifermin;cisplatin chemotherapy
26 Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT Completed NCT01931150 Phase 3 Topical Dapsone 5% Gel;oral antibiotics
27 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
28 Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT00771641 Phase 3
29 Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery Completed NCT00424255 Phase 3 Lapatinib
30 Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx Completed NCT00004234 Phase 3
31 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
32 Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery Completed NCT00002670 Phase 3 chemotherapy;cisplatin
33 Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Completed NCT00820248 Phase 3 cisplatin
34 Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00054561 Phase 3 isotretinoin
35 Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer Completed NCT00006481 Phase 3 Biafine cream
36 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003888 Phase 3 cisplatin;docetaxel;fluorouracil
37 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3 methotrexate;paclitaxel
38 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
39 Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00003809 Phase 3 cisplatin
40 Surgery and Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer That Can Be Removed During Surgery Completed NCT00003576 Phase 3 cisplatin;fluorouracil
41 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
42 Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer Recruiting NCT01772706 Phase 3
43 Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity Recruiting NCT01265849 Phase 3
44 DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer Recruiting NCT03237325 Phase 3 SGX942;Placebo
45 Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis. Recruiting NCT00964977 Phase 3
46 LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy Recruiting NCT01856478 Phase 3 methotrexate;afatinib
47 Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer Recruiting NCT03269344 Phase 3 Gabapentin;Placebo Oral Capsule
48 Resource Sparing Curative Radiotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck: The HYPNO Trial Recruiting NCT02765503 Phase 3
49 Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma Recruiting NCT01855451 Phase 3 Cetuximab;Cisplatin
50 Chemoradiotherapy With or Without Enteral Nutrition Intervention for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma Recruiting NCT02399306 Phase 3 nutrison;Docetaxel, cisplatin

Search NIH Clinical Center for Oral Squamous Cell Carcinoma

Genetic Tests for Oral Squamous Cell Carcinoma

Anatomical Context for Oral Squamous Cell Carcinoma

MalaCards organs/tissues related to Oral Squamous Cell Carcinoma:

39
Lymph Node, Lung, Endothelial, Skin, Bone, Tongue, Liver

Publications for Oral Squamous Cell Carcinoma

Articles related to Oral Squamous Cell Carcinoma:

(show top 50) (show all 2157)
id Title Authors Year
1
Upregulated Expression of Transient Receptor Potential Cation Channel Subfamily V Receptors in Mucosae of Patients with Oral Squamous Cell Carcinoma and Patients with a History of Alcohol Consumption or Smoking. ( 28081185 )
2017
2
Cancer stem cell markers in patterning differentiation and in prognosis of oral squamous cell carcinoma. ( 28631562 )
2017
3
The expression and significance of the HOXA7 gene in oral squamous cell carcinoma. ( 28529281 )
2017
4
PTEN allelic loss is an important mechanism in the late stage of development of oral leukoplakia into oral squamous cell carcinoma. ( 28858374 )
2017
5
Serum metabolomics in oral leukoplakia and oral squamous cell carcinoma. ( 28862226 )
2017
6
A comprehensive analysis of candidate gene signatures in oral squamous cell carcinoma. ( 28043142 )
2017
7
Evaluation of Genetic Polymorphisms in Glutathione S-Transferase Theta1, Glutathione S-Transferase Mu1, and Glutathione S-Transferase Mu3 in Oral Leukoplakia and Oral Squamous Cell Carcinoma with Deleterious Habits using Polymerase Chain Reaction. ( 28904918 )
2017
8
Role of microscopic spread beyond gross disease as an adverse prognostic factor in oral squamous cell carcinoma. ( 28528911 )
2017
9
Expression of T-lymphoma invasion and metastasis factor on the occurrence of oral squamous cell carcinoma. ( 28685528 )
2017
10
Diagnostic dilemma between medication-related osteonecrosis and oral squamous cell carcinoma in a mandibular lytic lesion. ( 28851496 )
2017
11
Leptin acts on neoplastic behavior and expression levels of genes related to hypoxia, angiogenesis, and invasiveness in oral squamous cell carcinoma. ( 28459203 )
2017
12
Complex integrated analysis of lncRNAs-miRNAs-mRNAs in oral squamous cell carcinoma. ( 28939059 )
2017
13
High HMGA2 Expression Correlates with Reduced Recurrence-free Survival and Poor Overall Survival in Oral Squamous Cell Carcinoma. ( 28373457 )
2017
14
Oral squamous cell carcinoma masquerading as gingival overgrowth. ( 28932153 )
2017
15
Long non-coding RNA MALAT1 promotes oral squamous cell carcinoma development via microRNA-125b/STAT3 axis. ( 28926115 )
2017
16
N-acetylneuraminic acid: A scrutinizing tool in oral squamous cell carcinoma diagnosis. ( 28928781 )
2017
17
Tropomyosin-1 acts as a potential tumor suppressor in human oral squamous cell carcinoma. ( 28182650 )
2017
18
Transcriptome analysis reveals differentially expressed lncRNAs between oral squamous cell carcinoma and healthy oral mucosa. ( 28415559 )
2017
19
PD-L1 Expression Confers Better Prognosis in Locally Advanced Oral Squamous Cell Carcinoma. ( 28314313 )
2017
20
Opposite effects of tumor protein D (TPD) 52 and TPD54 on oral squamous cell carcinoma cells. ( 28339026 )
2017
21
KLK4 silencing inhibits the growth of oral squamous cell carcinoma through Wnt/I^-catenin signaling pathway. ( 28150891 )
2017
22
The prognostic value of T Lymphoma Invasion and Metastasis 1 (TIAM1) expression in oral squamous cell carcinoma. ( 27862620 )
2017
23
In silico analysis of pathways activation landscape in oral squamous cell carcinoma and oral leukoplakia. ( 28580171 )
2017
24
Molecular basis of oral squamous cell carcinoma in young patients: Is it any different from older patients? ( 28922483 )
2017
25
Pancreatic adenocarcinoma up-regulated factor has oncogenic functions in oral squamous cell carcinoma. ( 27706833 )
2017
26
Epigenetics in oral squamous cell carcinoma. ( 28932035 )
2017
27
Downregulation of miR-377 Promotes Oral Squamous Cell Carcinoma Growth and Migration by Targeting HDAC9. ( 28267394 )
2017
28
Icaritin Reduces Oral Squamous Cell Carcinoma Progression via the Inhibition of STAT3 Signaling. ( 28085115 )
2017
29
Trends in oral squamous cell carcinoma: Diagnosis for effective, evidence-based treatment 2017. ( 28932025 )
2017
30
Saliva protein biomarkers and oral squamous cell carcinoma. ( 28039438 )
2017
31
SIPA1 promotes invasion and migration in human oral squamous cell carcinoma by ITGB1 and MMP7. ( 28237246 )
2017
32
LncRNA, TUG1 regulates the oral squamous cell carcinoma progression possibly via interacting with Wnt/I^-catenin signaling. ( 28119088 )
2017
33
The circadian clock gene PER2 plays an important role in tumor suppression through regulating tumor-associated genes in human oral squamous cell carcinoma. ( 28535015 )
2017
34
Genomic profile of oral squamous cell carcinomas with an adjacent leukoplakia or with an erythroleukoplakia that evolved after the treatment of primary tumor: A report of two cases. ( 28901451 )
2017
35
Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma. ( 28910982 )
2017
36
Current mouse models of oral squamous cell carcinoma: Genetic and chemically induced models. ( 28939069 )
2017
37
Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment. ( 27922697 )
2017
38
Clinical Roles of Interleukin-6 and STAT3 in Oral Squamous Cell Carcinoma. ( 27744625 )
2017
39
Isomahanine induces endoplasmic reticulum stress and simultaneously triggers p38A MAPK-mediated apoptosis and autophagy in multidrug-resistant human oral squamous cell carcinoma cells. ( 28075474 )
2017
40
Paraoxonase 3 promotes cell proliferation and metastasis by PI3K/Akt in oral squamous cell carcinoma. ( 27923688 )
2017
41
High expression of stathmin 1 is a strong prognostic marker in oral squamous cell carcinoma patients treated by docetaxel-containing regimens. ( 26590596 )
2017
42
Macrophages and prognosis of oral squamous cell carcinoma: a systematic review. ( 28940738 )
2017
43
Gimeracil enhances the antitumor effect of cisplatin in oral squamous cell carcinoma cells in vitro and in vivo. ( 28927087 )
2017
44
Combined Analysis of Vascular Endothelial Growth Factor Expression with Cyclooxygenase-2 and Mast Cell Density in Oral Squamous Cell Carcinoma. ( 27577989 )
2017
45
Circulating high mobility group AT-hook 2 and pleomorphic adenoma gene 1 in blood of patients with oral squamous cell carcinoma. ( 28650082 )
2017
46
Silencing of long non-coding RNA CCAT2 depressed malignancy of oral squamous cell carcinoma via Wnt/I^-catenin pathway. ( 28671055 )
2017
47
Interaction Between Rare Variants in NOTCH1 and Betel Quid Chewing in Oral Squamous Cell Carcinoma. ( 28910158 )
2017
48
Long noncoding RNA HAS2-AS1 mediates hypoxia-induced invasiveness of oral squamous cell carcinoma. ( 28485478 )
2017
49
Shrinkage in oral squamous cell carcinoma: An analysis of tumor and margin measurements in vivo, post-resection, and post-formalin fixation. ( 28917966 )
2017
50
Oridonin induces G2/M cell cycle arrest and apoptosis in human oral squamous cell carcinoma. ( 28935563 )
2017

Variations for Oral Squamous Cell Carcinoma

Cosmic variations for Oral Squamous Cell Carcinoma:

9 (show top 50) (show all 540)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM3724309 ZNF536 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1935G>C p.Q645H 9
2 COSM10645 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.527G>T p.C176F 9
3 COSM44894 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.874A>T p.K292* 9
4 COSM43592 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.395A>T p.K132M 9
5 COSM45615 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.776A>G p.D259G 9
6 COSM10659 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.817C>T p.R273C 9
7 COSM11133 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.725G>C p.C242S 9
8 COSM10646 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.725G>A p.C242Y 9
9 COSM10662 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 9
10 COSM10724 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.839G>C p.R280T 9
11 COSM45248 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.805A>T p.S269C 9
12 COSM10727 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.438G>A p.W146* 9
13 COSM43606 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.734G>A p.G245D 9
14 COSM10988 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.772G>A p.E258K 9
15 COSM10704 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.844C>T p.R282W 9
16 COSM44633 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.583A>T p.I195F 9
17 COSM45135 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.673-1G>T p.? 9
18 COSM11677 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.925C>T p.P309S 9
19 COSM11166 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.406C>T p.Q136* 9
20 COSM10859 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.814G>T p.V272L 9
21 COSM10958 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.797G>T p.G266V 9
22 COSM10758 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.659A>G p.Y220C 9
23 COSM44821 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.412G>A p.A138T 9
24 COSM44335 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.958A>T p.K320* 9
25 COSM43708 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.422G>A p.C141Y 9
26 COSM43947 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.614A>G p.Y205C 9
27 COSM45636 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.934A>T p.T312S 9
28 COSM11066 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.578A>T p.H193L 9
29 COSM43564 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.708C>A p.Y236* 9
30 COSM10992 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.844C>G p.R282G 9
31 COSM10768 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.535C>T p.H179Y 9
32 COSM10648 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.524G>A p.R175H 9
33 COSM43714 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.836G>A p.G279E 9
34 COSM10812 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.722C>T p.S241F 9
35 COSM10660 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.818G>A p.R273H 9
36 COSM45607 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.676G>A p.G226S 9
37 COSM45794 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.421T>G p.C141G 9
38 COSM44126 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.507G>A p.M169I 9
39 COSM11073 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1024C>T p.R342* 9
40 COSM44338 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.845G>A p.R282Q 9
41 COSM44233 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.840A>C p.R280S 9
42 COSM10905 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.451C>T p.P151S 9
43 COSM10738 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.542G>A p.R181H 9
44 COSM10739 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.481G>A p.A161T 9
45 COSM44220 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.417G>T p.K139N 9
46 COSM45077 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.390C>T p.L130L 9
47 COSM10654 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.637C>T p.R213* 9
48 COSM44218 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.536A>C p.H179P 9
49 COSM10672 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.577C>T p.H193Y 9
50 COSM45612 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.685T>C p.C229R 9

Copy number variations for Oral Squamous Cell Carcinoma from CNVD:

7 (show top 50) (show all 164)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 41848 10 24600000 38000000 Deletion Oral squamous cell carcinoma
2 49706 11 110400000 121200000 Deletion Oral squamous cell carcinoma
3 50988 11 121200000 130800000 Deletion Oral squamous cell carcinoma
4 51497 11 12700000 16200000 Deletion Oral squamous cell carcinoma
5 57445 11 63400000 77100000 Amplification CCND1 Oral squamous cell carcinoma
6 57446 11 63400000 77100000 Amplification EMS1 Oral squamous cell carcinoma
7 57448 11 63400000 77100000 Amplification FGF3 Oral squamous cell carcinoma
8 57449 11 63400000 77100000 Amplification FGF4 Oral squamous cell carcinoma
9 57450 11 63400000 77100000 Amplification PPP1CA Oral squamous cell carcinoma
10 57451 11 63400000 77100000 Amplification TAOS1 Oral squamous cell carcinoma
11 58782 11 69471367 69490165 Amplification ORAOV1 Oral squamous cell carcinoma
12 74065 13 1 4500000 Deletion Oral squamous cell carcinoma
13 74179 13 101700000 110300000 Deletion Oral squamous cell carcinoma
14 75170 13 17900000 115169878 Noncopy numberrandom LOH Oral squamous cell carcinoma
15 76133 13 27800000 55300000 Deletion Oral squamous cell carcinoma
16 76134 13 27800000 87700000 Deletion Oral squamous cell carcinoma
17 76220 13 28900000 40100000 Deletion Oral squamous cell carcinoma
18 76534 13 32200000 40100000 Deletion Oral squamous cell carcinoma
19 76709 13 35500000 40100000 Deletion Oral squamous cell carcinoma
20 77109 13 40100000 59600000 Deletion Oral squamous cell carcinoma
21 78640 13 55300000 73300000 Deletion Oral squamous cell carcinoma
22 79281 13 68600000 87700000 Deletion Oral squamous cell carcinoma
23 79539 13 73300000 79000000 Deletion Oral squamous cell carcinoma
24 79879 13 79000000 87700000 Deletion Oral squamous cell carcinoma
25 80342 13 90000000 98200000 Deletion Oral squamous cell carcinoma
26 80629 13 95000000 110300000 Deletion Oral squamous cell carcinoma
27 80632 13 95000000 115169878 Deletion Oral squamous cell carcinoma
28 80634 13 95000000 98200000 Deletion Oral squamous cell carcinoma
29 83034 14 19100000 33300000 Deletion Oral squamous cell carcinoma
30 84231 14 24600000 33300000 Deletion Oral squamous cell carcinoma
31 85052 14 37800000 50900000 Deletion Oral squamous cell carcinoma
32 86340 14 58100000 67900000 Deletion Oral squamous cell carcinoma
33 86341 14 58100000 73800000 Deletion Oral squamous cell carcinoma
34 87452 14 73800000 79300000 Deletion Oral squamous cell carcinoma
35 89133 15 1 19000000 Noncopy numberrandom LOH Oral squamous cell carcinoma
36 90246 15 20700000 40100000 Deletion Oral squamous cell carcinoma
37 91779 15 33600000 40100000 Deletion Oral squamous cell carcinoma
38 91783 15 33600000 44800000 Deletion Oral squamous cell carcinoma
39 92363 15 40100000 49500000 Deletion Oral squamous cell carcinoma
40 92861 15 44800000 49500000 Deletion Oral squamous cell carcinoma
41 93371 15 52900000 72700000 Deletion Oral squamous cell carcinoma
42 95627 15 78300000 89100000 Deletion Oral squamous cell carcinoma
43 95629 15 78300000 98500000 Deletion Oral squamous cell carcinoma
44 106754 17 1 16000000 Deletion Oral squamous cell carcinoma
45 106831 17 1 24000000 Noncopy numberrandom LOH Oral squamous cell carcinoma
46 106907 17 1 81195210 Deletion Oral squamous cell carcinoma
47 106970 17 10700000 50200000 Deletion Oral squamous cell carcinoma
48 109058 17 24000000 81195210 Noncopy numberrandom LOH Oral squamous cell carcinoma
49 112186 17 38100000 57600000 Deletion Oral squamous cell carcinoma
50 114590 17 50200000 70900000 Deletion Oral squamous cell carcinoma

Expression for Oral Squamous Cell Carcinoma

Search GEO for disease gene expression data for Oral Squamous Cell Carcinoma.

Pathways for Oral Squamous Cell Carcinoma

Pathways related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 124)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.16 AKT1 CASP3 CCND1 CDH1 CDKN1B CTNNB1
2
Show member pathways
13.98 AKT1 CASP3 CCND1 CDH1 CDKN1B CDKN2A
3
Show member pathways
13.84 AKT1 CCND1 CDKN1B CDKN2A EGFR HRAS
4
Show member pathways
13.61 AKT1 CTNNB1 EGFR HRAS KRT19 MMP2
5
Show member pathways
13.52 AKT1 CASP3 CTNNB1 EGFR HRAS MMP2
6
Show member pathways
13.52 AKT1 CASP3 CCND1 CDKN1B EGFR HRAS
7
Show member pathways
13.49 AKT1 CASP3 CCND1 EGFR HRAS MMP2
8
Show member pathways
13.4 AKT1 CASP3 CDH1 CTNNB1 EGFR HRAS
9
Show member pathways
13.4 AKT1 CASP3 CDH1 CTNNB1 EGFR HRAS
10
Show member pathways
13.12 AKT1 CASP3 CDH1 CTNNB1 HRAS TP53
11
Show member pathways
13.02 AKT1 CDKN2A EGFR HRAS MMP9 VEGFA
12
Show member pathways
13.02 AKT1 CCND1 CDKN1B CTNNB1 EGFR HRAS
13
Show member pathways
13.01 AKT1 CASP3 CTNNB1 HRAS MMP9 TP53
14
Show member pathways
12.93 AKT1 CASP3 CDH1 CTNNB1 HRAS TP53
15
Show member pathways
12.88 AKT1 CASP3 CCND1 CTNNB1 EGFR HRAS
16
Show member pathways
12.85 AKT1 CDH1 CTNNB1 EGFR HRAS VEGFA
17
Show member pathways
12.83 AKT1 CDKN1B EGFR HRAS TP53
18 12.81 AKT1 CASP3 EGFR HRAS TP53
19
Show member pathways
12.77 AKT1 CTNNB1 MMP2 MMP9 VEGFA
20
Show member pathways
12.77 AKT1 CASP3 EGFR HRAS TP53
21 12.77 AKT1 CASP3 CCND1 CDKN1B CTNNB1 EGFR
22
Show member pathways
12.72 AKT1 CASP3 HRAS VEGFA VEGFC
23
Show member pathways
12.72 AKT1 CTNNB1 EGFR HRAS MMP2 TP53
24
Show member pathways
12.68 AKT1 CCND1 CDKN1B CDKN2A TP53
25
Show member pathways
12.63 AKT1 CASP3 CDH1 CTNNB1 EGFR HRAS
26
Show member pathways
12.62 AKT1 CASP3 CCND1 CDH1 CDKN1B CDKN2A
27 12.6 AKT1 CASP3 CCND1 CDH1 CDKN1B CDKN2A
28
Show member pathways
12.57 AKT1 CASP3 CTNNB1 EGFR HRAS TP53
29 12.56 AKT1 CCND1 CDKN2A CTNNB1 HRAS TP53
30 12.56 CASP3 CCND1 CDKN1B CDKN2A EGFR HRAS
31 12.55 AKT1 CCND1 CDH1 CTNNB1 TP53
32
Show member pathways
12.55 CCND1 CDKN1B CTNNB1 EGFR HRAS
33
Show member pathways
12.53 CASP3 EGFR HRAS VEGFA VEGFC
34
Show member pathways
12.52 AKT1 CCND1 CDKN1B HRAS TP53
35
Show member pathways
12.5 CASP3 CCND1 CDKN1B CDKN2A TP53
36
Show member pathways
12.5 AKT1 EGFR HRAS VEGFA VEGFC
37 12.49 CCND1 CDH1 CDKN1B CDKN2A TP53
38
Show member pathways
12.46 AKT1 CCND1 CDKN1B EGFR HRAS TP53
39
Show member pathways
12.45 CCND1 CDKN1B CDKN2A TP53
40
Show member pathways
12.42 AKT1 CCND1 CTNNB1 HRAS
41
Show member pathways
12.42 AKT1 CCND1 EGFR HRAS
42 12.42 CASP3 CCND1 CDKN1B CDKN2A HRAS TP53
43
Show member pathways
12.38 AKT1 CASP3 CCND1 CDKN1B EGFR HRAS
44
Show member pathways
12.37 AKT1 EGFR HRAS VEGFA VEGFC
45
Show member pathways
12.36 AKT1 CASP3 CCND1 TP53
46
Show member pathways
12.34 AKT1 CASP3 CDKN1B HRAS TP53 VEGFA
47 12.26 AKT1 CASP3 CCND1 CTNNB1 EGFR HRAS
48
Show member pathways
12.25 AKT1 CASP3 HRAS TP53
49
Show member pathways
12.25 AKT1 CCND1 CTNNB1 EGFR HRAS MMP2
50 12.23 AKT1 CASP3 CTNNB1 HRAS

GO Terms for Oral Squamous Cell Carcinoma

Cellular components related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 catenin complex GO:0016342 8.96 CDH1 CTNNB1
2 flotillin complex GO:0016600 8.62 CDH1 CTNNB1

Biological processes related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 42)
id Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.99 AKT1 CTNNB1 EGFR HRAS PDPN TP53
2 positive regulation of apoptotic process GO:0043065 9.97 AKT1 CASP3 CDKN2A CTNNB1 MMP9 TP53
3 positive regulation of gene expression GO:0010628 9.94 CTNNB1 HRAS TP53 VEGFA
4 cell cycle arrest GO:0007050 9.92 CDKN1B CDKN2A HRAS TP53
5 response to organic cyclic compound GO:0014070 9.91 CASP3 CCND1 CDKN1B EGFR
6 response to drug GO:0042493 9.91 CASP3 CCND1 CDH1 CDKN1B CTNNB1 VEGFC
7 G1/S transition of mitotic cell cycle GO:0000082 9.89 AKT1 CCND1 CDKN1B CDKN2A
8 lung development GO:0030324 9.88 CTNNB1 EGFR PDPN VEGFA
9 response to organic substance GO:0010033 9.88 AKT1 CASP3 CCND1 CDH1
10 response to hypoxia GO:0001666 9.88 CASP3 CDKN1B MMP2 VEGFA VEGFC
11 negative regulation of cell proliferation GO:0008285 9.88 CDKN1B CDKN2A CTNNB1 HRAS TP53 VEGFC
12 extracellular matrix disassembly GO:0022617 9.86 CDH1 MMP2 MMP9
13 cellular response to organic cyclic compound GO:0071407 9.86 AKT1 CASP3 CDKN1B
14 Ras protein signal transduction GO:0007265 9.85 CDKN2A HRAS TP53
15 positive regulation of endothelial cell proliferation GO:0001938 9.85 AKT1 VEGFA VEGFC
16 positive regulation of MAP kinase activity GO:0043406 9.83 EGFR HRAS VEGFA
17 positive regulation of cell migration GO:0030335 9.83 EGFR HRAS MMP9 VEGFA
18 cellular response to growth factor stimulus GO:0071363 9.82 AKT1 CTNNB1 EGFR
19 positive regulation of neuron apoptotic process GO:0043525 9.81 CASP3 CTNNB1 TP53
20 positive regulation of cell proliferation GO:0008284 9.8 CCND1 CDKN1B CTNNB1 EGFR HRAS VEGFA
21 cellular response to reactive oxygen species GO:0034614 9.78 AKT1 EGFR MMP9
22 cellular response to cadmium ion GO:0071276 9.77 AKT1 EGFR MMP9
23 single organismal cell-cell adhesion GO:0016337 9.77 CDH1 CRNN CTNNB1 EGFR PDPN
24 positive regulation of epithelial cell proliferation GO:0050679 9.76 EGFR HRAS VEGFA VEGFC
25 response to X-ray GO:0010165 9.74 CASP3 CCND1 TP53
26 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.73 CASP3 CDKN1B CDKN2A
27 positive regulation of blood vessel endothelial cell migration GO:0043536 9.72 AKT1 VEGFA VEGFC
28 response to estradiol GO:0032355 9.72 CASP3 CCND1 CDKN1B CTNNB1 EGFR
29 positive regulation of neuroblast proliferation GO:0002052 9.71 CTNNB1 VEGFA VEGFC
30 negative regulation of apoptotic process GO:0043066 9.7 AKT1 CASP3 CDKN1B EGFR MMP9 TP53
31 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.69 AKT1 VEGFA
32 positive regulation of cellular component movement GO:0051272 9.68 PDPN VEGFA
33 mitotic G1 DNA damage checkpoint GO:0031571 9.68 CCND1 TP53
34 positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.65 AKT1 EGFR
35 epidermal growth factor receptor signaling pathway GO:0007173 9.65 EGFR HRAS
36 positive regulation of mast cell chemotaxis GO:0060754 9.64 VEGFA VEGFC
37 cellular response to indole-3-methanol GO:0071681 9.63 CDH1 CTNNB1
38 positive regulation of protein phosphorylation GO:0001934 9.43 AKT1 CCND1 EGFR HRAS MMP9 VEGFA
39 response to UV-A GO:0070141 8.8 AKT1 CCND1 EGFR
40 multicellular organism development GO:0007275 10.21 AKT1 EGFR HOPX PDPN TP53 VEGFA
41 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.21 AKT1 CDKN2A CTNNB1 EGFR HRAS TP53
42 positive regulation of transcription, DNA-templated GO:0045893 10.1 AKT1 CDH1 CDKN2A CTNNB1 EGFR TP53

Molecular functions related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.8 AKT1 CCND1 CTNNB1 EGFR TP53
2 protein phosphatase binding GO:0019903 9.46 CDKN1B CTNNB1 EGFR TP53
3 nitric-oxide synthase regulator activity GO:0030235 9.37 AKT1 EGFR
4 disordered domain specific binding GO:0097718 9.26 CTNNB1 TP53
5 protein kinase binding GO:0019901 9.17 AKT1 CCND1 CDKN1B CDKN2A CTNNB1 EGFR
6 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.13 CASP3 CDKN1B CDKN2A
7 protein binding GO:0005515 10.28 AKT1 CASP3 CCND1 CDH1 CDKN1B CDKN2A

Sources for Oral Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....